CA2146192C - Hydrogels polyioniques insolubles renfermant du xanthane - Google Patents

Hydrogels polyioniques insolubles renfermant du xanthane

Info

Publication number: CA2146192C
Authority: CA; Canada
Prior art keywords: chitosan; xanthan; hydrogels; hydrogel; xylanase
Prior art date: 1995-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002146192A

Other languages

English (en)

Other versions

CA2146192A1 (fr

Inventor

Esteban Chornet

Severian Dumitriu

Pierre Vidal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kemestrie Inc

Original Assignee

Universite de Sherbrooke

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-03

Filing date

1995-04-03

Publication date

1999-04-06

1995-04-03 Application filed by Universite de Sherbrooke filed Critical Universite de Sherbrooke

1995-04-03 Priority to CA002146192A priority Critical patent/CA2146192C/fr

1996-10-04 Publication of CA2146192A1 publication Critical patent/CA2146192A1/fr

1999-04-06 Application granted granted Critical

1999-04-06 Publication of CA2146192C publication Critical patent/CA2146192C/fr

2015-04-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000017 hydrogel Substances 0.000 title claims abstract description 92
229920001285 xanthan gum Polymers 0.000 title claims abstract description 77
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 title claims abstract description 70
229920000831 ionic polymer Polymers 0.000 title description 8
229920001661 Chitosan Polymers 0.000 claims abstract description 112
102000004190 Enzymes Human genes 0.000 claims abstract description 46
108090000790 Enzymes Proteins 0.000 claims abstract description 46
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims abstract description 24
239000004365 Protease Substances 0.000 claims abstract description 24
108091005804 Peptidases Proteins 0.000 claims abstract description 22
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 21
239000003814 drug Substances 0.000 claims abstract description 21
229940079593 drug Drugs 0.000 claims abstract description 20
229940088598 enzyme Drugs 0.000 claims description 42
239000000203 mixture Substances 0.000 claims description 20
239000004367 Lipase Substances 0.000 claims description 6
210000004027 cell Anatomy 0.000 claims description 6
102000004882 Lipase Human genes 0.000 claims description 5
108090001060 Lipase Proteins 0.000 claims description 5
235000019421 lipase Nutrition 0.000 claims description 5
-1 orthomycin Natural products 0.000 claims description 4
238000005538 encapsulation Methods 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
108090000623 proteins and genes Proteins 0.000 claims description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
229940059442 hemicellulase Drugs 0.000 claims description 3
108010002430 hemicellulase Proteins 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
UXRHCHSWRDOIED-UHFFFAOYSA-N Adenomycin Natural products OC1C(OS(O)(=O)=O)C(OC(=O)C(CO)N)C(OCC2C(C(O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)C(O)C1OC1OC(CO)C(O)C(O)C1N UXRHCHSWRDOIED-UHFFFAOYSA-N 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
229930186147 Cephalosporin Natural products 0.000 claims description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
229930182566 Gentamicin Natural products 0.000 claims description 2
229930193140 Neomycin Natural products 0.000 claims description 2
URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
108010059993 Vancomycin Proteins 0.000 claims description 2
UXRHCHSWRDOIED-QVEOBRIHSA-N [(1r,2s,3s,4s,5r,6r)-4-[(2r,3s,4r,5s,6s)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,5-dihydroxy-6-sulfooxycyclohexyl] (2s)-2-amino-3-hydroxypropanoate Chemical compound O([C@H]1[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)[C@H]([C@@H]([C@@H]1O)OS(O)(=O)=O)OC(=O)[C@H](CO)N)[C@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1N UXRHCHSWRDOIED-QVEOBRIHSA-N 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
229940124587 cephalosporin Drugs 0.000 claims description 2
150000001780 cephalosporins Chemical class 0.000 claims description 2
229960005091 chloramphenicol Drugs 0.000 claims description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
229960000975 daunorubicin Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
229960000318 kanamycin Drugs 0.000 claims description 2
229930027917 kanamycin Natural products 0.000 claims description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
229930182823 kanamycin A Natural products 0.000 claims description 2
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
229960000282 metronidazole Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
229960004927 neomycin Drugs 0.000 claims description 2
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
229960001404 quinidine Drugs 0.000 claims description 2
URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 2
229960001544 sulfathiazole Drugs 0.000 claims description 2
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
229960003165 vancomycin Drugs 0.000 claims description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
229940088623 biologically active substance Drugs 0.000 claims 2
239000004100 Oxytetracycline Substances 0.000 claims 1
229930182555 Penicillin Natural products 0.000 claims 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
239000004098 Tetracycline Substances 0.000 claims 1
229960000723 ampicillin Drugs 0.000 claims 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
238000013270 controlled release Methods 0.000 claims 1
229960003276 erythromycin Drugs 0.000 claims 1
229960000625 oxytetracycline Drugs 0.000 claims 1
235000019366 oxytetracycline Nutrition 0.000 claims 1
229940049954 penicillin Drugs 0.000 claims 1
210000001236 prokaryotic cell Anatomy 0.000 claims 1
229960002180 tetracycline Drugs 0.000 claims 1
229930101283 tetracycline Natural products 0.000 claims 1
235000019364 tetracycline Nutrition 0.000 claims 1
150000003522 tetracyclines Chemical class 0.000 claims 1
229930188428 trichomycin Natural products 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 30
239000000499 gel Substances 0.000 abstract description 25
238000010668 complexation reaction Methods 0.000 abstract description 22
230000021736 acetylation Effects 0.000 abstract description 19
238000006640 acetylation reaction Methods 0.000 abstract description 19
238000000034 method Methods 0.000 abstract description 13
238000009792 diffusion process Methods 0.000 abstract description 9
230000002378 acidificating effect Effects 0.000 abstract description 8
238000002360 preparation method Methods 0.000 abstract description 8
230000007935 neutral effect Effects 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 abstract description 4
239000012620 biological material Substances 0.000 abstract description 2
238000013268 sustained release Methods 0.000 abstract description 2
239000012730 sustained-release form Substances 0.000 abstract description 2
229910002056 binary alloy Inorganic materials 0.000 abstract 1
239000000243 solution Substances 0.000 description 50
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000004005 microsphere Substances 0.000 description 16
239000000758 substrate Substances 0.000 description 15
230000008961 swelling Effects 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 10
229920000447 polyanionic polymer Polymers 0.000 description 10
235000019441 ethanol Nutrition 0.000 description 9
230000014759 maintenance of location Effects 0.000 description 9
239000008351 acetate buffer Substances 0.000 description 8
230000009102 absorption Effects 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
229920000867 polyelectrolyte Polymers 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
238000013019 agitation Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
108010093096 Immobilized Enzymes Proteins 0.000 description 5
235000010443 alginic acid Nutrition 0.000 description 5
229920000615 alginic acid Polymers 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000002245 particle Substances 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
229920002101 Chitin Polymers 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000011148 porous material Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
229920002683 Glycosaminoglycan Polymers 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
244000309464 bull Species 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
239000003822 epoxy resin Substances 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
229920000647 polyepoxide Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000008364 bulk solution Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000007654 immersion Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
229960000292 pectin Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
238000004321 preservation Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
229920001221 xylan Polymers 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000223261 Trichoderma viride Species 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
241000589636 Xanthomonas campestris Species 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
VQQSDVBOXQHCHU-SKPOXZENSA-N antelmycin Chemical compound O[C@@H]1[C@@H](N)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)[C@@H]1[C@@H](N)[C@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 VQQSDVBOXQHCHU-SKPOXZENSA-N 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
238000005452 bending Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920006184 cellulose methylcellulose Polymers 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000012568 clinical material Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000011368 organic material Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000005588 protonation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
KUIXZSYWBHSYCN-UHFFFAOYSA-L remazol brilliant blue r Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC(S(=O)(=O)CCOS([O-])(=O)=O)=C1 KUIXZSYWBHSYCN-UHFFFAOYSA-L 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000000352 supercritical drying Methods 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Microbiology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

CA002146192A 1995-04-03 1995-04-03 Hydrogels polyioniques insolubles renfermant du xanthane Expired - Fee Related CA2146192C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002146192A CA2146192C (fr)	1995-04-03	1995-04-03	Hydrogels polyioniques insolubles renfermant du xanthane

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002146192A CA2146192C (fr)	1995-04-03	1995-04-03	Hydrogels polyioniques insolubles renfermant du xanthane

Publications (2)

Publication Number	Publication Date
CA2146192A1 CA2146192A1 (fr)	1996-10-04
CA2146192C true CA2146192C (fr)	1999-04-06

Family

ID=4155559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002146192A Expired - Fee Related CA2146192C (fr)	1995-04-03	1995-04-03	Hydrogels polyioniques insolubles renfermant du xanthane

Country Status (1)

Country	Link
CA (1)	CA2146192C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8088832B2 (en)	2006-04-05	2012-01-03	Woodland Biofuels Inc.	System and method for converting biomass to ethanol via syngas
CN114990100B (zh) *	2022-06-24	2024-01-30	陕西科技大学	一种乳糖酶微胶囊制备方法及利用其制备低乳糖液态羊乳

1995
- 1995-04-03 CA CA002146192A patent/CA2146192C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2146192A1 (fr)	1996-10-04

Legal Events

Date	Code	Title	Description
1996-12-18	EEER	Examination request
2008-04-03	MKLA	Lapsed

Publication	Publication Date	Title
US5620706A (en)	1997-04-15	Polyionic insoluble hydrogels comprising xanthan and chitosan
Dumitriu et al.	1994	Polyionic hydrogels obtained by complexation between xanthan and chitosan: their properties as supports for enzyme immobilization
Peniche et al.	2003	Chitosan: an attractive biocompatible polymer for microencapsulation
Pellá et al.	2018	Chitosan-based hydrogels: From preparation to biomedical applications
Chan et al.	2009	Semisynthesis of a controlled stimuli-responsive alginate hydrogel
US5089272A (en)	1992-02-18	Process for producing capsules having a permeability-controllable membrane
Mi et al.	1999	Chitosan–polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. I. Effect of phosphorous polyelectrolyte complex and enzymatic hydrolysis of polymer
Lin et al.	2005	pH-sensitive polyelectrolyte complex gel microspheres composed of chitosan/sodium tripolyphosphate/dextran sulfate: swelling kinetics and drug delivery properties
Chandy et al.	1999	Evaluation of modified alginate‐chitosan‐polyethylene glycol microcapsules for cell encapsulation
Mi et al.	1999	Chitosan–polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. II. Effect of pH‐dependent ionic crosslinking or interpolymer complex using tripolyphosphate or polyphosphate as reagent
Yang et al.	2013	pH-sensitive interpenetrating network hydrogels based on chitosan derivatives and alginate for oral drug delivery
Huguet et al.	1996	Calcium-alginate beads coated with polycationic polymers: comparison of chitosan and DEAE-dextran
CA1338958C (fr)	1997-03-04	Matrices d'hydrogel biodegradables pour la liberation prolongee d'agents pharmacologiquement actifs
US5041292A (en)	1991-08-20	Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
Denkbaş et al.	2004	Norfloxacin-loaded chitosan sponges as wound dressing material
CA2513483C (fr)	2011-11-29	Microspheres hydrogel injectables de systeme aqueux a deux phases
Cheng et al.	2003	Studies on nerve cell affinity of biodegradable modified chitosan films
CN108653741B (zh)	2021-06-25	一种金属有机配位聚合物包裹的天然丝胶蛋白微球及其制备方法和应用
WO2000015272A1 (fr)	2000-03-23	Cellules vivantes immobilisees dans un polymere, et applications correspondantes
CN108676177B (zh)	2020-11-06	一种以纳米淀粉粒子为骨架的智能水凝胶加工方法
Goycoolea et al.	2003	Effect of chemical crosslinking on the swelling and shrinking properties of thermal and pH‐responsive chitosan hydrogels
Hu et al.	2015	Preparation and characterization of composite hydrogel beads based on sodium alginate
CN119074638B (zh)	2026-03-13	一种基于氧化灵芝多糖的多肽水凝胶及应用
KR101929293B1 (ko)	2018-12-14	이중 이온가교된 상호침투 네트워크형 알지네이트-셀룰로오스 비드 및 이의 제조방법
CA2146192C (fr)	1999-04-06	Hydrogels polyioniques insolubles renfermant du xanthane